Selecting Remote Measurement Technologies to Optimize Assessment of Function in Early Alzheimer's Disease: A Case Study

Andrew P Owens, Chris Hinds, Nikolay V Manyakov, Thanos G Stavropoulos, Grace Lavelle, Dianne Gove, Ana Diaz-Ponce, Dag Aarsland, Andrew P Owens, Chris Hinds, Nikolay V Manyakov, Thanos G Stavropoulos, Grace Lavelle, Dianne Gove, Ana Diaz-Ponce, Dag Aarsland

Abstract

Despite the importance of function in early Alzheimer's disease (AD), current measures are outdated and insensitive. Moreover, COVID-19 has heighted the need for remote assessment in older people, who are at higher risk of being infection and are particularly advised to use social distancing measures, yet the importance of diagnosis and treatment of dementia remains unchanged. The emergence of remote measurement technologies (RMTs) allows for more precise and objective measures of function. However, RMT selection is a critical challenge. Therefore, this case study outlines the processes through which we identified relevant functional domains, engaged with stakeholder groups to understand participants' perspectives and worked with technical experts to select relevant RMTs to examine function. After an extensive literature review to select functional domains relevant to AD biomarkers, quality of life, rate of disease progression and loss of independence, functional domains were ranked and grouped by the empirical evidence for each. For all functional domains, we amalgamated feedback from a patient advisory board. The results were prioritized into: highly relevant, relevant, neutral, and less relevant. This prioritized list of functional domains was then passed onto a group of experts in the use of RMTs in clinical and epidemiological studies to complete the selection process, which consisted of: (i) identifying relevant functional domains and RMTs; (ii) synthesizing proposals into final RMT selection, and (iii) verifying the quality of these decisions. Highly relevant functional domains were, "difficulties at work," "spatial navigation and memory," and "planning skills and memory required for task completion." All functional domains were successfully allocated commercially available RMTs that make remote measurement of function feasible. This case study provides a set of prioritized functional domains sensitive to the early stages of AD and a set of RMTs capable of targeting them. RMTs have huge potential to transform the way we assess function in AD-monitoring for change and stability continuously within the home environment, rather than during infrequent clinic visits. Our decomposition of RMT and functional domain selection into identify, synthesize, and verify activities, provides a pragmatic structure with potential to be adapted for use in future RMT selection processes.

Keywords: Alzheimer's disease; activities of daily living; dementia—Alzheimer disease; function; mild cognitive impairment—MCI; remote measurement technologies; telemedicine.

Copyright © 2020 Owens, Hinds, Manyakov, Stavropoulos, Lavelle, Gove, Diaz-Ponce and Aarsland.

References

    1. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation. Early Alzheimer's Disease: Developing Drugs For Treatment, Guidelines for Industry. (2018). Available online at: .
    1. Rafii MS, Aisen PS. Alzheimer's disease clinical trials: moving toward successful prevention. CNS Drugs. (2019) 33:99–106. 10.1007/s40263-018-0598-1
    1. U.S. Department of Health Human Services FDA Center for Drug Evaluation Research,U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance Health Qual Life Outcomes. (2006) 4:79.
    1. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. . An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's disease cooperative study. Alzheimer Dis Assoc Disord. (1997) 11 (Suppl 2):S33–9. 10.1097/00002093-199700112-00005
    1. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, et al. . Alzheimer's disease cooperative study. mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. (2004) 61:59–66. 10.1001/archneur.61.1.59
    1. Tomaszewski Farias S, Mungas D, Harvey DJ, Simmons A, Reed BR, Decarli C. The measurement of everyday cognition: development and validation of a short form of the everyday cognition scales. Alzheimer's Dement. (2011) 7:593–601. 10.1016/j.jalz.2011.02.007
    1. Koster N, Knol DL, Uitdehaag BM, Scheltens P, Sikkes SA. The sensitivity to change over time of the Amsterdam IADL questionnaire(©). Alzheimers Dement. (2015) 11:1231–40. 10.1016/j.jalz.2014.10.006
    1. Zhang X, Li C, Zhang M. Psychosocial risk factors of Alzheimer's disease. Zhonghua Yi Xue Za Zhi. (1999) 79:335–8.
    1. He YL, Zhang XK, Zhang MY. Psychosocial risk factors for Alzheimer's disease. Hong Kong J Psychiatry. (2000) 10:2–7.
    1. Marioni RE, Proust-Lima C, Amieva H, Brayne C, Matthews FE, Dartigues JF, et al. . Social activity, cognitive decline and dementia risk: a 20-year prospective cohort study. BMC Public Health. (2015) 15:1089. 10.1186/s12889-015-2426-6
    1. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. . Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on mild cognitive impairment. J Intern Med. (2004) 256:240–6. 10.1111/j.1365-2796.2004.01380.x
    1. Pérès K, Chrysostome V, Fabrigoule C, Orgogozo JM, Dartigues JF, Barberger-Gateau P. Restriction in complex activities of daily living in MCI. Neurology. (2006). 67:461–6. 10.1212/01.wnl.0000228228.70065.f1
    1. Lee MT, Jang Y, Chang WY. How do impairments in cognitive functions affect activities of daily living functions in older adults? PLoS ONE. (2019) 14:e0218112. 10.1371/journal.pone.0218112
    1. Jekel K, Damian M, Wattmo C, Hausner L, Bullock R, Connelly PJ, et al. . Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. Alzheimers Res Ther. (2015) 7:17. 10.1186/s13195-015-0099-0
    1. Perneczky R, Pohl C, Sorg C, Hartmann J, Tosic N, Grimmer T, et al. . Impairment of activities of daily living requiring memory or complex reasoning as part of the MCI syndrome. Int J Geriatr Psychiatry. (2006) 21:158–62. 10.1002/gps.1444
    1. Grigsby J, Kaye K, Baxter J, Shetterly SM, Hamman RF. Executive cognitive abilities and functional status among community-dwelling older persons in the San Luis Valley health and aging study. J Am Geriatr Soc. (1998) 46:590–6. 10.1111/j.1532-5415.1998.tb01075.x
    1. Cahn-Weiner DA, Malloy PF, Boyle PA, Marran M, Salloway S. Prediction of functional status from neuropsychological tests in community-dwelling elderly individuals. Clin Neuropsychol. (2000) 14:187–95. 10.1076/1385-4046(200005)14:2;1-Z;FT187
    1. Farias ST, Lau K, Harvey D, Denny KG, Barba C, Mefford AN. Early functional limitations in cognitively normal older adults predict diagnostic conversion to mild cognitive impairment. J Am Geriatr Soc. (2017) 65:1152–8. 10.1111/jgs.14835
    1. Farias ST, Mungas D, Jagust W. Degree of discrepancy between self and other-reported everyday functioning by cognitive status: dementia, mild cognitive impairment, and healthy elders. Int J Geriatr Psychiatry. (2005) 20:827–34. 10.1002/gps.1367
    1. Cahn DA, Malloy PF, Salloway S, Rogg J, Gillard E, Kohn R, et al. . Subcortical hyperintensities on MRI and activities of daily living in geriatric depression. J Neuropsychiatry Clin Neurosci. (1996) 8:404–11.
    1. Farias ST, Mungas D, Reed B, Haan MN, Jagust WJ. Everyday functioning in relation to cognitive functioning and neuroimaging in community-dwelling Hispanic and non-Hispanic older adults. J Int Neuropsychol Soc. (2004) 10:342–54. 10.1017/S1355617704103020
    1. Daly E, Zaitchik D, Copeland M, Schmahmann J, Gunther J, Albert M. Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol. (2000) 57:675–80. 10.1001/archneur.57.5.675
    1. Davis MM, Freeman M, Kaye J, Vuckovic N, Buckley DI. A systematic review of clinician and staff views on the acceptability of incorporating remote monitoring technology into primary care. Telemed J E Health. (2014) 20:428–38. 10.1089/tmj.2013.0166
    1. Czaja S, Gold M, Bain LJ, Hendrix JA, Carrillo MC. Potential roles of digital technologies in clinical trials. Alzheimers Dement. (2017) 13:1075–6. 10.1016/j.jalz.2017.08.001
    1. Steinman MA, Perry L, Perissinotto CM. Meeting the care needs of older adults isolated at home during the COVID-19 pandemic. JAMA Intern Med. (2020) 180:819–20. 10.1001/jamainternmed.2020.1661
    1. Clinical Trials Transformation Initiative CTTI Technology Selection Tool. Available online at: .
    1. Polhemus AM, Novák J, Ferrao J, Simblett S, Radaelli M, Locatelli P, et al. . Human-centered design strategies for device selection in mhealth programs: development of a novel framework and case study. JMIR mHealth and uHealth. (2020) 8:e16043. 10.2196/16043
    1. Stavropoulos TG, Papastergiou A, Mpaltadoros L, Nikolopoulos S, Kompatsiaris I. IoT wearable sensors and devices in elderly care: a literature review. Sensors. (2020) 20:2826. 10.3390/s20102826
    1. ROADMAP Guidelines for use of Smart Devices as a Measure of RWE. Available online at: .
    1. Stavropoulos TG, Meditskos G, Kompatsiaris I. DemaWare2: Integrating sensors, multimedia and semantic analysis for the ambient care of dementia. Pervasive Mob. Comput. (2017) 34:126–45. 10.1016/j.pmcj.2016.06.006
    1. Doherty A, Jackson D, Hammerla N, Plötz T, Olivier P, Granat MH, et al. . Large scale population assessment of physical activity using wrist worn accelerometers: The UK Biobank Study. PLoS ONE. (2017) 12:e0169649. 10.1371/journal.pone.0169649
    1. Simon HA. The Sciences of the Artificial. Cambridge, MA: MIT Press; (2019).
    1. Black R, Greenberg B, Ryan JM, Posner H, Seeburger J, Amatniek J, et al. Scales as outcome measures for Alzheimer's disease. Alzheimers Dement. (2009) 5:324–39. 10.1016/j.jalz.2009.05.667

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren